The potential role of systemic inflammatory markers in predicting recurrence in early-stage cervical cancer

Matteo Bruno, Nicolò Bizzarri, Elena Teodorico, Camilla Certelli, Valerio Gallotta, Luigi Pedone Anchora, Anna Fagotti, Francesco Fanfani, Giovanni Scambia, Maria Gabriella Ferrandina

Research output: Contribution to journalArticle


Introduction: The influence of systemic inflammatory markers on early-stage cervical cancer (ECC) patients is contradictory. No previous study analyzed whether these markers may be suggestive of recurrence. The aim of this study was to assess whether the inflammatory markers level of patients with recurrence during surveillance was different from those of patients without recurrence representing a risk factor for recurrence. Methods: Retrospective, single-center, observational study. Patients with 2009 FIGO EEC surgically treated between 2012 and 2019 were included. Baseline inflammatory markers were evaluated on the results of the complete blood count (CBC) and coagulation tests. Inflammatory markers of relapsed patients were evaluated on the last CBC performed before the relapse diagnosis. Inflammatory markers of patients with no recurrence were evaluated on the available CBC taken at the same median follow-up time as the one from relapsed patients. Results: 174 patients were included. Baseline Systemic immune inflammation index (SII) > 663 and Systemic inflammation response index (SIRI) > 0.98 were associated with significant risk of recurrence. SII>663 and Neutrophil to lymphocyte ratio (NLR) > 2.41 were associated with increased risk of death. Significant changes between relapsed (n = 23) and non-relapsed (n = 151) patients in median values of SII (615 versus 490, p-value = 0.001), SIRI (0.74 versus 1.05, p-value = 0.005), NRL (2.95 versus 2.15, p-value = 0.0035), and MLR (0.26 versus 0.22 p-value = 0.020), showed that different levels of inflammatory markers could help identifying recurrent disease during surveillance. Conclusion: Baseline SII>663 and SIRI>0.98 were associated with increased risk of recurrence. Higher median values of SII, SIRI, NLR and MLR in relapsed patients highlight their potential association with recurrence.
Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalEuropean Journal of Surgical Oncology
Publication statusPublished - 2024


  • Early-stage cervical cancer
  • Prognosis
  • Systemic inflammation markers
  • Surveillance
  • Recurrence


Dive into the research topics of 'The potential role of systemic inflammatory markers in predicting recurrence in early-stage cervical cancer'. Together they form a unique fingerprint.

Cite this